Marksans Pharma Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.9 pts less than Nifty Microcap 250 and 5.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Marksans Pharma reported strong FY25 results with standalone revenue from operations rising to Rs. 1,174.37 crore from Rs. 853.27 crore in FY24, a growth of about 37.6%. Standalone profit after tax climbed to Rs. 188.27 crore from Rs. 133.76 crore, up roughly 40.7%. On a consolidated basis, revenue grew about 20.5% to Rs. 2,622.84 crore and PAT rose about 21.5% to Rs. 382.62 crore. Statutory auditor MSKA & Associates issued an unmodified (clean) opinion on both standalone and consolidated results. The Board has recommended a final dividend of Rs. 0.80 per share (face value Re. 1), an 80% payout subject to shareholder approval. The Board also appointed Mr. Srinivas Mishra as an Independent Director for 5 years and approved amendments to the ESOP 2024 scheme with a pool of 23 lakh options.
Strong double-digit revenue and profit growth, a clean audit opinion, and an 80% dividend payout are positive signals for shareholders. The new independent director brings banking and risk expertise to the Board. Overall, the results reinforce a positive growth and shareholder-friendly narrative, though consolidated PAT growth was modest at around 21.5%.